Project Grant R01AI187284
Award Date
7/18/25
Completion Date
6/30/30
Dollars Obligated
$689K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
This $408,375 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to elucidate phage resistance mechanisms in Mycobacterium abscessus (MAB) and assess how these can be leveraged to enhance the efficacy of antibiotic therapy. The overarching goal is to deepen the fundamental understanding of phage-mycobacteria interactions and apply this knowledge to develop...
This $240,878 Project Grant, awarded on June 2, 2025 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports planning activities for a future clinical trial to evaluate a novel treatment strategy for Mycobacterium abscessus pulmonary disease. The key objectives are to: 1) develop the detailed trial protocol and documentation, 2) secure the study drug and placebo, 3) identify additional enrollment...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $895,538 to Hackensack University Medical Center (HMH Hospitals Corporation) to develop shorter and more effective oral regimens for treating Mycobacterium abscessus pulmonary disease. The research aims to discover all-oral sterilizing drug regimens, either using FDA-approved agents or integrating novel preclinical and...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $155,227 to The Johns Hopkins University to generate proof-of-concept data on a novel strategy to treat Mycobacterium abscessus (MAB) chronic lung disease. The project aims to investigate whether a monoclonal antibody called CMTX-101 can disrupt MAB biofilms in the lungs, which would allow antibiotics...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $750,815 to the University of Maryland, Baltimore to conduct research on developing novel therapeutic approaches to treat mucormycosis, a deadly invasive fungal infection. The key research objectives are: Examining the role of the host cell hypoxia-response pathway and the ANGPTL4 protein in the pathogenesis of mucormycosis, and exploring the...
This $193,375 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to identify bacterial determinants that may contribute to variable treatment responses for tuberculosis (TB). The project, conducted by researchers at the Harvard T.H. Chan School of Public Health, aims to investigate the effects of clinically prevalent variants in the ESX1 secretion system on TB...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $565,149 to Health Research, Inc. Wadsworth Center Division to conduct research on RNA-based regulatory mechanisms in Mycobacterium tuberculosis (MTB). The primary objectives are to: Define the regulatory interactions of the sRNA MCR11 and its impact on gene expression in MTB. Characterize the roles of RNA-ABMR...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $711,993.00 to Boston Medical Center Corporation to conduct research on the impact of Mycobacterium tuberculosis (MTB) disease on HIV-1 immunity, evolution, and persistence. The research aims to examine how MTB disease affects the development of broadly potent HIV-1 neutralizing antibodies, the emergence of...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $300,001 to Fimbrion Therapeutics Inc. to develop novel heterocyclic inhibitors of the QcrB respiratory protein as potential treatments for infections caused by nontuberculous mycobacteria (NTM). The key objectives of this R&D project are to optimize the drug-like properties of the QcrB inhibitor compounds, demonstrate their potency...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $294,824 to the University of Massachusetts Medical School (UMass Medical) to investigate strategies for enhancing the efficacy of antibiotics against Mycobacterium tuberculosis (MTB) infections. The key objectives are to understand the mechanistic link between glutamine starvation, immune pressure vulnerability, and...